What Does the 503B Bulks List Mean for Patients?

What is the 503B bulks list, in plain English?

The 503B bulks list is the FDA's finalized list of raw drug ingredients (called “bulk drug substances”) for which the FDA has decided there is a clinical need for large compounding “outsourcing facilities” to use them. It is not a list of FDA-approved drugs, and being on it does not make a compounded product FDA-approved. The finalized list currently holds five other substances — not semaglutide, tirzepatide, or liraglutide.

Two terms do the heavy lifting here, so let's define them.

A “bulk drug substance” (also called an active pharmaceutical ingredient, or API) is the raw active material a medicine is made from — before it becomes a finished shot or pill.

An “outsourcing facility” is a facility that chooses to register with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act. It's often called a “503B.” It isn't defined by being big, and it isn't always a pharmacy — but in practice, these are the operations that make medicine in large batches. That's different from a “503A” pharmacy (Section 503A), which generally makes a medicine for one identified patient from a prescription.

Why does this list exist? Safety. Congress created the 503B framework in 2013, after a 2012 fungal-meningitis outbreak tied to contaminated compounded injections exposed serious risks in large-scale sterile compounding. The framework adds federal registration, manufacturing-quality rules, inspections, reporting, and limits on which raw ingredients a facility can use.

The two “doors” — how a 503B facility is allowed to use a raw ingredient

Here's the piece that clears up most of the confusion. A 503B facility can meet the raw-ingredient requirement through one of two doors:

1. Door #1 — The clinical-need list. The raw ingredient is on the 503B bulks list because the FDA found a clinical need for it.
2. Door #2 — The shortage list. The finished drug is on the FDA's official shortage list at the time it's made, shipped, and dispensed.

If either door is open — and the facility follows every other rule — it can compound from that raw ingredient. If both are shut, it can't. Keep these two doors in mind; the rest of this page is really just checking which doors are open for your drug.

What did the FDA actually propose in 2026 — and is it final?

On April 30, 2026, the FDA announced a proposal not to include semaglutide, tirzepatide, or liraglutide on the 503B bulks list, saying it did not find a clinical need for outsourcing facilities to make them from raw ingredients. This is a proposal, not a final determination. The FDA extended the public comment period to July 30, 2026, and will decide afterward.

Precision matters here, because the headlines got sloppy.

The FDA did not “remove” these drugs from the list — they were never on the finalized list to begin with. What the FDA did is propose not to add them. “Proposed not to include” is the accurate phrase, and it changes what's true today versus what might be true later.

The FDA's stated reasoning, in plain words: it didn't find enough evidence that outsourcing facilities have a clinical need to make these three from raw ingredients under the clinical-need list. The FDA was also clear that supply problems, backorders, convenience, and cost do not count as “clinical need” for this list — because shortages are handled separately (that's Door #2).

Here's the timeline, separating the 2024–2025 shortage wind-down from the separate 2026 bulks-list proposal:

What the headlines got wrong

We read a lot of coverage. A few claims kept showing up that aren't quite right — and getting them straight is exactly why this page deserves to exist.

What does the 503B bulks list mean for patients right now?

It depends on which drug you take. Semaglutide and tirzepatide are on neither the finalized 503B bulks list nor the FDA shortage list, so neither raw-ingredient door is open for large facilities to compound them. Liraglutide injection is currently on the shortage list, so that separate door may still be open for it — if every other 503B condition is met. Your drug changes your answer.

Most pages lump all three together. That's the biggest mistake, because they're in different spots. We built the matrix below by lining up the finalized 503B list, the FDA shortage list, and the pending proposal — the exact picture you'd otherwise have to reconstruct from several sources.

The RX Index 503B GLP-1 Patient Impact Matrix — verified July 2026

Sources: FDA proposal (Apr 30, 2026); FDA drug-shortage database; Federal Register; Orrick and Epstein Becker Green legal analyses. Liraglutide status can change — some presentations show recovery estimates as early as mid-2026 — so re-check before you rely on it.

Semaglutide and tirzepatide: Both doors are shut. Practically, large-scale compounded access to these two ended in 2025, when the shortages resolved and the grace periods ran out. If a company is still selling you cheap compounded “semaglutide” or “tirzepatide” with no documented, patient-specific reason, that's worth a hard look — we'll show you how below.

Liraglutide: This is the outlier. Its injection is still listed in shortage, which may keep the shortage door open for outsourcing facilities right now — if all the other conditions are met. Two honest notes: that status is close to flipping (some listings show recovery estimates arriving soon), and liraglutide is an older, once-daily GLP-1, while the newer weekly options (semaglutide, tirzepatide) came later. So “still available” doesn't automatically mean “the best fit for you.”

The obvious next question: how do you know which door applies to your medicine? That comes down to your pharmacy — and most people have never checked. Here's the two-minute way to do it.

503A vs. 503B: is any compounded GLP-1 still legal?

Yes, but only under specific conditions. This proposal addresses 503B use of these raw ingredients under the clinical-need list; it does not rewrite the 503A rules. Federal law — backed by recent court rulings — bars both 503A and 503B from making what's “essentially a copy” of an FDA-approved drug on a routine or large scale, unless that drug is in shortage. A narrow, patient-specific lane can still exist under 503A when a prescriber documents that a change makes a real difference for one identified patient.

Let's compare the two side by side.

Here's where people get tripped up. You'll read “503A pharmacies are unaffected.” That's true in a narrow legal sense — this proposal doesn't decide 503A rules. But it does not mean a 503A pharmacy can freely hand out compounded copies of Ozempic. When the semaglutide and tirzepatide shortages resolved in 2025, that already removed the main legal basis 503A pharmacies had for copying those drugs (per Orrick's legal analysis and the FDA). So the door many people imagine is open… mostly isn't.

There is a real, narrow lane: a 503A pharmacy can make a genuinely patient-specific version when a prescriber determines and documents that a change produces a significant difference for one identified patient — and every other 503A condition is met. An allergy to an inactive ingredient, a strength that isn't commercially made, or a different form can be relevant. But none of those automatically makes it legal. And adding a splash of vitamin B12 doesn't automatically make it “personalized” — the FDA has flagged some GLP-1-plus-B12 combinations as still counting as “essentially a copy.”

What if a company is still selling cheap compounded semaglutide or tirzepatide?

Treat it with caution — but don't use price alone to judge legality. For semaglutide and tirzepatide, neither raw-ingredient door is open, so ask for the legal pharmacy name, whether it's operating under 503A or 503B for your prescription, the source material, and the prescriber-documented reason. Compounded drugs are not FDA-approved and aren't reviewed for safety, effectiveness, or quality the way brand drugs are.

Here's our one honest, uncomfortable admission — followed by the reassurance you came for.

The uncomfortable part: a 503B outsourcing facility follows real manufacturing-quality rules (CGMP) and gets FDA inspections. That oversight is meaningful, and in some ways it's stricter than the baseline for a small 503A pharmacy. So “compounded” doesn't automatically mean “sketchy.”

But here's the pivot that matters for you: even a well-run 503B product is still not FDA-approved — it hasn't gone through the FDA's review for safety, effectiveness, and quality that a brand-name drug has. If a seller is skipping the FDA-approved product to offer you a cheaper copy of a drug that's no longer in shortage, that's the situation the rules now restrict — which means your supply could change or stop if the legal basis or sourcing changes. And if price is your worry (it is for almost everyone), the good news is that the FDA-approved options got dramatically cheaper this year. We'll get there next.

For context on why the FDA is leaning in: as of April 30, 2025, the FDA had received about 520 adverse-event reports tied to compounded semaglutide and 480 tied to compounded tirzepatide. The FDA adds two honest caveats — these are likely underreported (state-licensed pharmacies aren't required to report), and it often can't confirm the drug caused the event, since many reports look similar to side effects seen with the approved versions. Some reports involved dosing errors, a few serious enough to require hospitalization. Some medical groups, including the American Diabetes Association, have discouraged using compounded GLP-1s.

What are my real options now?

FDA-approved products go through the FDA's review for safety, effectiveness, and quality; compounded products don't. And current manufacturer and Medicare programs have made several FDA-approved options far cheaper than their old list prices — Zepbound runs about $299–$449/month through LillyDirect, Wegovy about $349–$499/month through NovoCare, the oral Wegovy pill starts near $149/month, and the Medicare GLP-1 Bridge caps eligible enrollees at $50/month. Your actual cost depends on coverage, dose, eligibility, and your clinician.

This is the part panic articles skip, and it's the part that actually helps. Compounded got popular because brand GLP-1s used to be $1,000+ a month. That math changed. Here's what the FDA-approved options look like now (prices below were checked against the named source for this update; eligibility, dose, and offer terms apply):

Sources: LillyDirect; NovoCare; CMS (Medicare GLP-1 Bridge). See our Medicare GLP-1 Bridge guide for who actually qualifies, and our guide to GLP-1 compounding rules after the shortages ended for the bigger picture.

Two things worth saying plainly. First, switching from a compounded product to an FDA-approved one should happen with a clinician, because the strength, concentration, and dosing schedule can differ — you don't want a gap or a jump. Second, we keep FDA-approved and compounded strictly separate on purpose. They are not the same thing, and we won't pretend otherwise.

If you'd rather not sort this alone, that's exactly what our tool is for. It weighs your state, coverage, medication preference, form, and budget, then shows a source-verified match.

When you're ready to talk to a provider about an FDA-approved option, one legitimate route is Ro (sponsored affiliate link, opens in a new tab), which currently lists FDA-approved Zepbound® (tirzepatide) and the newer oral orforglipron (Foundayo™), plus insurance help. (Affiliate link. Ro Body membership is $39 for the first month, then as low as $74/month with an annual plan paid upfront, or $149 month to month; the medication is charged separately.) If Ro isn't your fit, the tool above will point you elsewhere.

What should I do if my provider says my medication is changing?

Don't stop, switch, restart, or change your dose on your own because of a headline or a website. Ask your prescriber to name the pharmacy, explain why the program is changing, confirm your refill timeline, and give you a plan that fits your exact medication and history.

If you got an email that your source is changing, take a breath. This is a plan-it-out moment, not an emergency. Here are the five questions that get you clear answers fast — screenshot or print them.

Keep your own notes, but don't post photos of your prescription label publicly. And don't ration or double up doses to stretch a supply — some of the dosing errors the FDA has flagged came from measuring or calculating a dose incorrectly, or taking doses beyond the approved schedule.

What happens after July 30, 2026?

After the comment period closes, the FDA will review the input and either finalize its proposal or change it. The notices don't promise a specific decision date, so treat this as “proposal pending” until an official final determination is published. And watch the shortage list — a status change there could shift the answer even before a final determination.

We won't pretend to know the exact date. Here's how to read whatever comes next:

• ›If the FDA finalizes the non-inclusion: the three drugs stay off the clinical-need list. The separate shortage door would still exist, and every other 503B condition would still apply. A final determination governs what facilities can do — it isn't an individual prescription-cancellation notice.
• ›If the FDA changes the proposal: it could treat the three drugs differently. Don't assume the same outcome for all — liraglutide especially could break from the other two.
• ›If the FDA takes no quick action: nothing new happens the day after July 30. The status quo holds; the comment window simply closes and review continues.
• ›If the shortage list changes first: this is the one to watch for liraglutide. If its shortage resolves, the shortage door closes for it too — possibly before any final determination.

One thing we won't do: turn a public-comment deadline into “act now before your medicine disappears.” That's not what the deadline is. Anyone can submit a comment to the FDA (Docket FDA-2018-N-3240) through July 30 if they want their voice on the record — but it's not a countdown on your prescription.

What we actually verified

We think a health page should show its work. Here's what we checked, and against what.

What we did not verify: the legal basis behind every individual telehealth program, whether any one patient qualifies for a compounded exception, future FDA timing, or your personal medical fit. Those need your prescriber. “Which option may fit you best” is our editorial judgment based on the verified facts above — not legal or medical advice.

Frequently asked questions

The proposal is pending, the current answer for raw-ingredient compounding depends on your drug and its shortage status, and 503A follows a separate patient-specific framework. These short answers cover the remaining edge cases.

Sources

1. FDA — FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (Apr 30, 2026): fda.gov/news-events/press-announcements/…
2. Federal Register — List of Bulk Drug Substances… Under Section 503B, 91 FR 23431 (May 1, 2026), Docket FDA-2018-N-3240: federalregister.gov/documents/2026/05/01/2026-08552
3. Federal Register — comment-period extension to July 30, 2026: federalregister.gov/documents/2026/06/26/2026-12937
4. FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (wind-down dates): fda.gov/drugs/drug-alerts-and-statements/…
5. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (safety, caveats): fda.gov/drugs/drug-alerts-and-statements/…
6. FDA — Registered Outsourcing Facilities (503B database): fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
7. FDA — 503B Bulk Drug Substances List: fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
8. FDA — Drug Shortages database: fda.gov/drugs/drug-safety-and-availability/drug-shortages
9. U.S. Code — Section 503A (21 U.S.C. §353a) and Section 503B (21 U.S.C. §353b)
10. Orrick — FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs (503A limits; shortage pathway)
11. Epstein Becker Green — analysis of the 503B proposal (liraglutide shortage exception; GLP-1 + B12 combinations)
12. CMS — Medicare GLP-1 Bridge ($50 copay; July 1, 2026–Dec 31, 2027): cms.gov/medicare/coverage/…
13. Manufacturer pricing — LillyDirect (Zepbound); NovoCare (Wegovy)

The RX Index is an independent editorial publisher — not a pharmacy, a compounder, or a substitute for your doctor. This article is for general education and is not medical or legal advice.